Good News for UCB – Zacks.com

by admin on February 6, 2013

Good News for UCB
Zacks.com
In Dec 2012, UCB received the Japanese approval for Neupro and Cimzia for Parkinson's disease and restless legs syndrome, and for rheumatoid arthritis respectively. UCB expects combined sales of Cimzia, Vimpat and Neupro to reach at least €3.1 billion

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: